yes i take peptides · shopping companion

Orforglipron

Category · For Weight LossStatus · RUOCitations · 60

The verdict

An oral, non-peptide GLP-1 receptor agonist. The ACHIEVE-1 phase 3 trial in type 2 diabetes hit its primary endpoint — A1c down ~1.5%, weight down 7.6% on the 36 mg top dose at 40 weeks. The ATTAIN-1 phase 3 obesity trial showed 11.2% weight loss at 72 weeks. Pill, not injection.

By source — cost, legality, risk

Brand
Not available
None — Lilly FDA submission pending, decision H2 2026 / 2027
No FDA-approved orforglipron yet.
Compounded 503A pharmacy
Not meaningfully available
Not approved · small molecule, atypical for 503A
Small-molecule oral; no realistic compounding path pre-approval.
RUO research peptide
$100–$250/mo
Sold 'for research only'
Highest. Small-molecule synthesis is hard to verify by mass spec; identity-failures likely common pre-approval.
Gray-market raw
Varies — not on user's vendor list
Unregulated overseas import
Small molecule — gray path is Chinese chemical suppliers, not the peptide raws this vendor list covers. Identity verification by mass spec is even harder for a small molecule.

Sources · top 5 of 60

01Rosenstock J, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. The New England journal of medicine. 2025;393(11):1065-1076. PMID: 40544435.
02Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England journal of medicine. 2023;389(10):877-888. PMID: 37351564.
03Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England journal of medicine. 2025;393(18):1796-1806. PMID: 40960239.
04Sloop KW, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science translational medicine. 2024;16(778):eadp5765. PMID: 39693407.
05Pratt E, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes, obesity & metabolism. 2023;25(9):2634-2641. PMID: 37344954.